title: A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.
abstract: BACKGROUND
  Population transmission models of antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) use simplistic assumptions--typically constant, homogeneous rates--to represent the short-term risk and long-term effects of drug resistance. In contrast, within-host models of drug resistance allow for more detailed dynamics of host immunity, latent reservoirs of virus, and drug PK/PD. Bridging these two levels of modeling detail requires an understanding of the "levers"--model parameters or combinations thereof--that change only one independent observable at a time. Using the example of accidental tenofovir-based pre-exposure prophyaxis (PrEP) use during HIV infection, we will explore methods of implementing host heterogeneities and their long-term effects on drug resistance.
  
  
  RESULTS
  We combined and extended existing models of virus dynamics by incorporating pharmacokinetics, pharmacodynamics, and adherence behavior. We identified two "levers" associated with the host immune pressure against the virus, which can be used to independently modify the setpoint viral load and the shape of the acute phase viral load peak. We propose parameter relationships that can explain differences in acute and setpoint viral load among hosts, and demonstrate their influence on the rates of emergence and reversion of drug resistance. The importance of these dynamics is illustrated by modeling long-lived latent reservoirs of virus, through which past intervals of drug resistance can lead to failure of suppressive drug regimens. Finally, we analyze assumptions about temporal patterns of drug adherence and their impact on resistance dynamics, finding that with the same overall level of adherence, the dwell times in drug-adherent versus not-adherent states can alter the levels of drug-resistant virus incorporated into latent reservoirs.
  
  
  CONCLUSIONS
  We have shown how a diverse range of observable viral load trajectories can be produced from a basic model of virus dynamics using immunity-related "levers". Immune pressure, in turn, influences the dynamics of drug resistance, with increased immune activity delaying drug resistance and driving more rapid return to dominance of drug-susceptible virus after drug cessation. Both immune pressure and patterns of drug adherence influence the long-term risk of drug resistance. In the case of accidental PrEP use during infection, rapid transitions between adherence states and/or weak immunity fortifies the "memory" of previous PrEP exposure, increasing the risk of future drug resistance. This model framework provides a means for analyzing individual-level risks of drug resistance and implementing heterogeneities among hosts, thereby achieving a crucial prerequisite for improving population-level models of drug resistance.
authors: Epidemiological Modeling Group, Intellectual Ventures Laboratory, Washington, USA. abershteyn@intven.com
authors: Anna
authors: A
authors: Bershteyn
authors: Philip A
authors: PA
authors: Eckhoff
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D003198:Computer Simulation; D024882:Drug Resistance, Viral / Q000276:immunology*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology*; D006801:Humans; D055118:Medication Adherence; D018448:Models, Immunological; D063065:Organophosphonates; D000068698:Tenofovir; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine
references: AIDS. 1992 Oct;6(10):1085-94
references: 1361339
references: Annu Rev Phys Chem. 2007;58:35-55
references: 17037977
references: J Theor Biol. 2011 May 21;277(1):55-66
references: 21315731
references: J Theor Biol. 2004 Jan 7;226(1):95-109
references: 14637059
references: Science. 2010 Dec 10;330(6010):1551-7
references: 21051598
references: J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-11
references: 16010161
references: J Exp Med. 1999 Mar 15;189(6):991-8
references: 10075982
references: JAMA. 1989 Jun 9;261(22):3273-7
references: 2716163
references: Nat Rev Immunol. 2002 Jan;2(1):28-36
references: 11905835
references: N Engl J Med. 2012 Aug 2;367(5):399-410
references: 22784037
references: N Engl J Med. 2012 Aug 2;367(5):423-34
references: 22784038
references: J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):272-83
references: 15980686
references: AIDS. 2003 May 23;17(8):1151-6
references: 12819516
references: Biol Direct. 2011 Sep 12;6:42
references: 21910865
references: J Immunol. 2000 Jul 15;165(2):1082-92
references: 10878387
references: AIDS. 2007 Aug 20;21(13):1673-82
references: 17690564
references: Philos Trans R Soc Lond B Biol Sci. 2000 Aug 29;355(1400):1059-70
references: 11186307
references: PLoS One. 2010 Jun 08;5(6):e10981
references: 20544022
references: J Infect Dis. 1998 Dec;178(6):1812-5
references: 9815241
references: PLoS One. 2007 Sep 19;2(9):e875
references: 17878928
references: N Engl J Med. 2012 Aug 2;367(5):411-22
references: 22784040
references: Nat Med. 2012 Sep;18(9):1378-85
references: 22941277
references: Science. 1996 Apr 5;272(5258):74-9
references: 8600540
references: Antimicrob Agents Chemother. 2001 Oct;45(10):2733-9
references: 11557462
references: AIDS. 2008 May 31;22(9):1055-61
references: 18520349
references: Phys Rev Lett. 2006 Nov 3;97(18):188106
references: 17155585
references: AIDS. 2000 Oct 20;14(15):2283-91
references: 11089616
references: J Neurovirol. 2004;10 Suppl 1:58-66
references: 14982741
references: Mol Pharmacol. 1974 Mar;10(2):235-47
references: 4212316
references: J Theor Biol. 1998 Feb 7;190(3):201-14
references: 9514649
references: J Theor Biol. 2000 Apr 7;203(3):285-301
references: 10716909
references: Ann Intern Med. 2001 May 15;134(10):968-77
references: 11352698
references: AIDS. 1997 Dec;11(15):1799-806
references: 9412697
references: Antimicrob Agents Chemother. 2005 Aug;49(8):3361-6
references: 16048948
references: Sci Rep. 2011;1:185
references: 22355700
references: Retrovirology. 2007 Apr 06;4:25
references: 17417971
references: Curr Opin HIV AIDS. 2011 Mar;6(2):131-40
references: 21505388
references: Clin Infect Dis. 2011 Dec;53(12):1265-70
references: 21976467
references: J Theor Biol. 2010 Jan 7;262(1):1-13
references: 19766126
references: Science. 1998 Mar 27;279(5359):2103-6
references: 9516110
references: Nature. 1997 May 8;387(6629):183-8
references: 9144289
references: Ann Appl Stat. 2011;5(1):551-577
references: 23162677
references: Clin Infect Dis. 2001 Oct 15;33(8):1417-23
references: 11550118
references: PLoS One. 2011 Apr 15;6(4):e18165
references: 21525976
references: Science. 2007 Aug 17;317(5840):944-7
references: 17641165
references: Science. 1996 May 24;272(5265):1167-70
references: 8638160
references: J Exp Med. 1999 Sep 20;190(6):841-50
references: 10499922
references: J Antimicrob Chemother. 2011 Feb;66(2):240-50
references: 21118913
references: PLoS Comput Biol. 2009 Oct;5(10):e1000533
references: 19834532
references: J Antimicrob Chemother. 2004 May;53(5):696-9
references: 15044425
references: Clin Infect Dis. 2006 May 1;42(9):1333-9
references: 16586394
references: AAPS J. 2005 Oct 05;7(2):E390-407
references: 16353919
references: Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12381-6
references: 20616092
references: Clin Infect Dis. 2002 Jul 1;35(1):77-81
references: 12060878
references: Clin Infect Dis. 2008 Jun 15;46(12):1913-20
references: 18462100
references: J Infect Dis. 2004 May 15;189(10):1785-92
references: 15122514
references: Proc Biol Sci. 2000 Apr 22;267(1445):835-43
references: 10819155
references: J Virol. 2009 Aug;83(15):7641-8
references: 19458000
references: JAMA. 1996 Jul 10;276(2):105-10
references: 8656501
references: Science. 2010 Sep 3;329(5996):1168-74
references: 20643915
references: AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):901-10
references: 11461676
references: Proc Natl Acad Sci U S A. 2011 May 3;108(18):7613-8
references: 21502494
references: Nat Med. 2009 Aug;15(8):861-5
references: 19661993
references: Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17441-6
references: 17954909
references: AIDS. 2003 Dec 5;17(18):2581-91
references: 14685052